Catalyst Event
Novo Nordisk A/S (NVO) · Other
From KEDI Global Longevity Bio Index (KGLB)
3/19/2026, 12:00:00 AM
On March 19, 2026, the U.S. FDA is scheduled to approve Wegovy HD (semaglutide 7.2 mg) for adults with obesity or overweight, with a high price impact (≥10%) expected as this blockbuster approval significantly increases market potential.
Korean Translation
2026년 3월 19일, 미국 FDA는 비만 또는 과체중 성인을 위한 위고비 HD(세마글루타이드 7.2mg)를 승인할 예정이며, 블록버스터 약물 승인은 시장 잠재력을 크게 확대하므로 10% 이상의 높은 주가 영향이 예상됨.
Related Recent Events
Ionis Pharmaceuticals Inc (IONS) · Other
FDA target action (PDUFA) date for olezarsen for the treatment of severe hypertriglyceridemia (sHTG) following acceptance of sNDA for Priority Review. This is a major potential approval for a broad patient population, scheduled.
6/30/2026, 12:00:00 AM
Biogen Inc (BIIB) · Earnings Release
Q1 2026 earnings release (Low impact estimated as routine earnings releases typically see at least 1% volatility) scheduled.
5/6/2026, 12:00:00 AM
Bristol-Myers Squibb Co (BMY) · Earnings Release
Bristol-Myers Squibb is scheduled to announce its first-quarter 2026 financial results on April 30, 2026, scheduled.
4/30/2026, 12:00:00 AM
Eli Lilly and Co (LLY) · Earnings Release
Q1 2026 earnings release scheduled; a price impact of at least 1% is expected.
4/30/2026, 12:00:00 AM
Teva Pharmaceutical Industries Ltd (TEVA) · Earnings Release
Teva is scheduled to release its first quarter 2026 financial results and host a conference call on April 29, 2026; importance is estimated at Medium as earnings reports typically drive significant price volatility, expected.
4/29/2026, 12:00:00 AM
Sanofi (SNY) · Earnings Release
First quarter 2026 earnings results are scheduled to be released on April 23, 2026. This is expected to have a low impact as a routine financial update, scheduled.
4/23/2026, 12:00:00 AM